The FOR 2240 Symposium “Innovative concepts in anti-inflammatory and anti(lymph)angiogenic therapies in the eye” will be held from 20-21 October 2017 on the Life Sciences Campus of the University of Cologne, Germany at the Centre for Molecular Medicine Cologne.
The goal of the symposium is to promote the most important findings of the FOR 2240 research unit and integrate them into a larger context.
The FOR 2240 is a German Research Foundation (DFG) Research Unit based at the Department of Ophthalmology, University Hospital of Cologne.
The central goal of the FOR 2240 is the investigation of the pathogenesis of aberrant immune and neovascularisation processes of the eye and the development of innovative new therapeutic strategies.
Prof. Dr. Kari Alitalo, U of Helsinki, Finland | Prof. Dr. Minas T. Coroneo, U of NSW, Sydney, Australia
Prof. Dr. Cornelia Halin, ETH Zurich, Switzerland | Prof. Dr. David G. Jackson, U of Oxford, UK
Prof. Dr. Martine J. Jager, U of Leiden, NL | Prof. Dr. Ulrich Kalinke, U of Hannover, Germany
Prof. Dr. Friedemann Kiefer, MPI Molecular Biomedicine, Münster, Germany
Prof. Dr. Jerry Y. Niederkorn, U of Texas Southwestern Medical Center, Dallas TX, USA
Prof. Dr. Daniel Saban, Duke U, Durham NC, USA | Prof. Dr. Jonathan P. Sleeman, U of Heidelberg,
Prof. Dr. Andreas Stahl, Albert-Ludwigs-U, Freiburg i.Br., Germany
Cologne: Prof. Dr. Claus Cursiefen, Cologne, FOR 2240 Speaker & PI
Prof. Dr. Thomas Langmann, FOR 2240 Vice-Speaker & PI
PD Dr. Felix Bock, FOR 2240 PI | Prof. Dr. Ludwig M. Heindl, FOR 2240 PI
Prof. Dr. Philipp Steven, FOR 2240 PI
Registration is required for this event. To register, send an email to email@example.com. Last call for registration: 17.10.2017, 12:00 noon.